Show simple item record

dc.contributor.authorChristensen, Christian
dc.contributor.authorJonsdottir-Buch, Sandra Mjoll
dc.contributor.authorSigurjonsson, Olafur Eysteinn
dc.date.accessioned2020-06-18T15:41:42Z
dc.date.available2020-06-18T15:41:42Z
dc.date.issued2020-04-15
dc.date.submitted2020-06
dc.identifier.citationChristensen C, Jonsdottir-Buch SM, Sigurjonsson OE. Effects of amotosalen treatment on human platelet lysate bioactivity: A proof-of-concept study. PLoS One. 2020;15(4):e0220163. Published 2020 Apr 15. doi:10.1371/journal.pone.0220163en_US
dc.identifier.pmid32294080
dc.identifier.doi10.1371/journal.pone.0220163
dc.identifier.urihttp://hdl.handle.net/2336/621448
dc.descriptionTo access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked Downloaden_US
dc.description.abstractBackground: Clinical application of mesenchymal stromal cells (MSCs) usually requires an in vitro expansion step to reach clinically relevant numbers. In vitro cell expansion necessitates supplementation of basal mammalian cell culture medium with growth factors. To avoid using supplements containing animal substances, human platelet lysates (hPL) produced from expired and pathogen inactivated platelet concentrates can be used in place of fetal bovine serum. However, globally, most transfusion units are currently not pathogen inactivated. As blood banks are the sole source of platelet concentrates for hPL production, it is important to ensure product safety and standardized production methods. In this proof-of-concept study we assessed the feasibility of producing hPL from expired platelet concentrates with pathogen inactivation applied after platelet lysis by evaluating the retention of growth factors, cytokines, and the ability to support MSC proliferation and tri-lineage differentiation. Methodology/principal findings: Bone marrow-derived MSCs (BM-MSCs) were expanded and differentiated using hPL derived from pathogen inactivated platelet lysates (hPL-PIPL), with pathogen inactivation by amotosalen/ultraviolet A treatment applied after lysis of expired platelets. Results were compared to those using hPL produced from conventional expired pathogen inactivated platelet concentrates (hPL-PIPC), with pathogen inactivation applied after blood donation. hPL-PIPL treatment had lower concentrations of soluble growth factors and cytokines than hPL-PIPC treatment. When used as supplementation in cell culture, BM-MSCs proliferated at a reduced rate, but more consistently, in hPL-PIPL than in hPL-PIPC. The ability to support tri-lineage differentiation was comparable between lysates. Conclusion/significance: These results suggest that functional hPL can be produced from expired and untreated platelet lysates by applying pathogen inactivation after platelet lysis. When carried out post-expiration, pathogen inactivation may provide a valuable solution for further standardizing global hPL production methods, increasing the pool of starting material, and meeting future demand for animal-free supplements in human cell culturing.en_US
dc.language.isoenen_US
dc.publisherPublic Library of Scienceen_US
dc.relation.urlhttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0220163en_US
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7159197/en_US
dc.titleEffects of amotosalen treatment on human platelet lysate bioactivity: A proof-of-concept study.en_US
dc.typeArticleen_US
dc.identifier.eissn1932-6203
dc.contributor.department1The Blood Bank, The National University Hospital of Iceland, Reykjavik, Iceland. 2Faculty of Medicine, Biomedical Center, University of Iceland, Reykjavik, Iceland. 3Platome Biotechnology, Hafnarfjörður, Iceland. 4School of Science and Engineering, University of Reykjavik, Reykjavik, Iceland.en_US
dc.identifier.journalPloS oneen_US
dc.rights.accessOpen Access - Opinn aðganguren_US
dc.departmentcodeNAF12
dc.source.journaltitlePloS one
dc.source.volume15
dc.source.issue4
dc.source.beginpagee0220163
dc.source.endpage
refterms.dateFOA2020-06-18T15:41:43Z
dc.source.countryUnited States


Files in this item

Thumbnail
Name:
Effects ....pdf
Size:
1.913Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record